Jennifer Atkinson
Psychiatric/Mental Health · Spring, TXNPI 1710666821
Payments from drug & device makers
Across 157 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$561
- Johnson & Johnson$436
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$262
- Axsome Therapeutics, Inc.$261
- Otsuka America Pharmaceutical, Inc.$249
- Alkermes, Inc.$222
- plus $1K from 11 others
What the payments were for
- Food & beverage$3,046100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $561 |
| Johnson & Johnson | 14 | $436 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $262 |
| Axsome Therapeutics, Inc. | 13 | $261 |
| Otsuka America Pharmaceutical, Inc. | 15 | $249 |
| Alkermes, Inc. | 9 | $222 |
| E.r. Squibb & Sons, L.L.C. | 9 | $191 |
| Teva Pharmaceuticals USA, Inc. | 9 | $162 |
| Vanda Pharmaceuticals Inc. | 9 | $158 |
| Neurocrine Biosciences, Inc. | 5 | $120 |
| Lundbeck LLC | 5 | $113 |
| Corium, LLC | 7 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $94 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Almatica Pharma LLC | 2 | $37 |
| Tempus AI, Inc | 1 | $19 |
| Indivior Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA$150
How this compares
$3,046 in reported general payments places this provider in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyzine Hcl | 11 | $152 |
| Aripiprazole | 18 | $147 |
| Buspirone Hcl | 20 | $101 |
| Trazodone Hcl | 16 | $43 |
| Sertraline Hcl | 13 | $16 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $37 | $1613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Spring
- Malcolm DuncanSpring$33K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.